Cost-effectiveness acceptability curve of probabilistic sensitivity analysis for iptacopan vs SOC. The distribution of each parameter used in the analysis is detailed in Table 1. Across all conventionally accepted WTP thresholds in the United States (ie, $50 000-$150 000 per QALY) iptacopan monotherapy is favored over SOC in 100% of 10 000 iterations.